Pfizer, Inc. has announced a Phase II mesothelioma drug study for malignant mesothelioma cancer patients. Before any new drug may be released to the market, it must complete three phases of clinical trials that evaluate its safety, possible side effects and effectiveness and compare the new drug to placebos and other treatments for effectiveness in […]
The post Pfizer Begins Phase II Mesothelioma Drug Study appeared first on Blumenthal & Gruber.
